May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Photodynamic Therapy And Intravitreal Triamcinolone For Exsudative Age Related Macular Degeneration
Author Affiliations & Notes
  • L. El Matri
    Ophthalmology, Hedi Rais Institute of Ophthalmology, Tunis, Tunisia
  • K. Baklouti
    Ophthalmology, Nabeul Hospital, Nabeul, Tunisia
  • F. Mghaieth
    Ophthalmology, Hedi Rais Institute of Ophthalmology, Tunis, Tunisia
  • O. Charfi Ben Ammar
    Ophthalmology, Hedi Rais Institute of Ophthalmology, Tunis, Tunisia
  • S. Ben Rejeb
    Ophthalmology, Hedi Rais Institute of Ophthalmology, Tunis, Tunisia
  • R. Baccouri
    Ophthalmology, Hedi Rais Institute of Ophthalmology, Tunis, Tunisia
  • M. Bukta
    Ophthalmology, Hedi Rais Institute of Ophthalmology, Tunis, Tunisia
  • Footnotes
    Commercial Relationships  L. El Matri, None; K. Baklouti, None; F. Mghaieth, None; O. Charfi Ben Ammar, None; S. Ben Rejeb, None; R. Baccouri, None; M. Bukta, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 3162. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. El Matri, K. Baklouti, F. Mghaieth, O. Charfi Ben Ammar, S. Ben Rejeb, R. Baccouri, M. Bukta; Photodynamic Therapy And Intravitreal Triamcinolone For Exsudative Age Related Macular Degeneration . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3162.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the effect of intravitreal triamcinolone acetonide on the outcome of patients with exsudative age related macular degeneration (AMD) before or after they are treated by photodynamic therapy (PTD). Methods: The prospective study included 34 eyes of 32 patients with neovascular AMD who received intravitreal triamcinolone acetonide (4 mg). Mean follow up time was 8.4 months (range: 3 to 18 months). Patients were divided into 3 groups: – group I: 15 patients (16 eyes) ineligibles for PDT – group II: 10 patients planned for PDT but waiting for healthcare insurance coverage – group III: 7 patients (8 eyes) have already been treated by PDT but they evolved to enlargement of neovascular membrane and visual loss Results: Visual acuity increased in 65% of cases, from CF – 0.05 up to 0.05 – 0.2. – group I: visual acuity having improved to 0.16 in 7 cases after 1 to 3 months, PDT was performed and led to stabilization of lesions. – group II: visual acuity increased in 3 cases and remained stable in 5 cases without neovascular membrane extension, thus PDT was indicated 1 to 4 months after the diagnosis. – group III: visual acuity was stabilized with reduction of subretinal fluid exsudation and no extension of neovascular membrane. Intravitreal triamcinolone acetonide was repeated within 4 months in 5 cases. Intraocular pressure increased temporarily in 1 case. Two patients developed acute endophtalmitis 2 days after intravitreal injection. It resolved without vitrectomy and cleared with systemic antibiotics and local steroids and antibiotics treatment after 10 and 14 days. Increasing in the degree of cataract was noted in the majority of cases. No cases of retinal detachment or proliferative retinopathy occurred. Conclusions: Intravitreal triamcinolone acetonide may be considered as a complementary treatment to PDT in some cases of exsudative AMD.

Keywords: age–related macular degeneration • endophthalmitis • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×